Welcome!

News Feed Item

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

Summary

The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug's performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.

A growing understanding of the signaling pathways underlying SLE pathophysiology including, but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of novel, and more importantly, first-in-class targeted therapeutics entering the developmental pipeline. In particular, a high level of investment in the development of cytokine-blocking strategies is evident, as therapies targeting the interferon pathway are relatively common in the pipeline.

Scope

- The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs.
- A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy
- In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy
- Overview of how innovation products are contributing to the market for SLE therapeutics
- Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes
- The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation
- First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets

Reasons to buy

The report will assist the business development strategies of companies that wish to develop novel therapies with improved benefits to existing treatments. It will also be of interest to companies seeking to expand their pipeline portfolio through licensing agreements and co-development deals. Primarily, the report will allow clients to identify and understand market opportunities and the emerging competitive environment. It will also allow you to -
- Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
- Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
- Understand the distribution of the pipeline programs by phase of development, molecule type and molecular target
- Identify the list of first-in-class programs that are potentially open to deal-making opportunities
- Understand the first-in-class developmental programs and gauge the current clinical effectiveness based on animal models

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 The Case for Innovation in Systemic Lupus Erythematosus 7
2.2 Growing Opportunities for Biologic Products 7
2.3 Diversification of Molecular Targets 7
2.4 Innovative First-in-Class Product Developments Remain Attractive 8
2.5 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 8
2.6 Sustained Innovation 8
3 Systemic Lupus Erythematosus 9
3.1 Disease Overview 9
3.2 Epidemiology 9
3.3 Disease Pathophysiology 10
3.4 Disease Symptoms 10
3.5 Environmental and Genetic Predisposition 11
3.6 Diagnosis 11
3.7 Disease Severity Assessments 12
3.7.1 PGA 12
3.7.2 SLEDAI 12

3.7.3 BILAG 13
3.7.4 SRI 13
3.8 Lupus Nephritis 13
3.9 Pharmacotherapy Algorithm 14
4 Clinical and Commercial Landscape 16
4.1 Corticosteroids 16
4.2 Antimalarials 16
4.3 Cytotoxic Chemotherapy 16
4.4 Biologics 17
4.4.1 Benlysta (belimumab) 17
4.5 Comparative Strengths and Weaknesses of Traditional Therapeutics 19
4.5.1 Corticosteroids vs Cytotoxic Therapeutics 19
4.5.2 Comparison of Immunosuppressants: Cyclosporine vs Azathioprine or Cyclophosphamide 21
4.5.3 Cyclophosphamide vs Azathioprine 23
4.5.4 Cyclophosphamide vs Mycophenolate Mofetil 23
4.5.5 Mycophenolate Mofetil vs Azathioprine 23
4.5.6 Biologics vs Immunosuppressants 25
4.6 Current Unmet Needs in the Systemic Lupus Erythematosus Market 27
5 Assessment of Pipeline Product Innovation 28
5.1 Overview of Pipeline Products for Systemic Lupus Erythematosus 28

5.2 Frequently Targeted Molecular Target Families 29
5.3 Comparative Distribution of Programs between the Systemic Lupus Erythematosus Market and Pipeline by Therapeutic Target Family 30
5.4 Comparative Efficacy and Safety of Pipeline Programs 31
5.5 Comparative Distribution of Programs with First-in-Class and Established Targets 33
5.6 Pipeline Programs Targeting Established Molecular Targets 35
5.7 First-in-class Pipeline Programs with Novel Molecular Targets 37
6 First-in-Class Target and Pipeline Program Evaluation 39
6.1 Cytokines and Receptors 39
6.1.1 Pipeline Programs Targeting IFN-? 39
6.1.2 Pipeline Programs Targeting CD74 43
6.1.3 Pipeline Programs Targeting B7 Related Protein 44
6.1.4 Pipeline Programs Targeting IL-21 46
6.1.5 Pipeline Programs Targeting IL-17 49
6.1.6 Pipeline Programs Targeting High Mobility Protein Box 1 51
6.1.7 Pipeline Programs Targeting APRIL 53
6.2 B and T Cell Antigens 55
6.2.1 Pipeline Programs Targeting CD4 55
6.2.2 Pipeline Programs Targeting CD40L 57
6.2.3 Pipeline Programs which Target Fc?R2b (CD32b) 60
6.2.4 Pipeline Programs which Target CD19 62
6.2.5 Pipeline Programs which Target CD22 64
6.3 Intracellular Kinase 67

6.3.1 Pipeline Programs which Target Spleen Tyrosine Kinase 67
6.4 Others 70
6.4.1 Pipeline Programs which Target Immunoproteasome subunit 7 (IMP7) 70
6.4.2 Pipeline Programs which Target ILT-7 71
7 Conclusions 72
8 Deals and Strategic Consolidations 74
8.1 Licensing Agreements 74
8.2 Co-development Deals 76
8.2.1 First-in-Class Developmental Programs Not Involved in Co-development Deals or Licensing Deals 78
9 Appendix 79
9.1 References 79
9.2 Abbreviations 88
9.3 Methodology 89
9.4 Contact Us 89
9.5 Disclaimer 89

List of Tables

Table 1: SLEDAI Index 12
Table 2: Classification of Lupus Nephritis 14
Table 3: Pipeline, Global, First-in-class Modulators of B7-Related Protein, Scientific Assessment 44
Table 4: Pipeline, Global, First-in-Class Modulators of IL-17, Scientific Assessment 49
Table 5: Pipeline, Global, First-in-class Modulators of APRIL, Scientific Assessment 53
Table 6: Pipeline, Global, First-in-class Modulators of CD4, Scientific Assessment 55
Table 7: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Scientific Assessment 60
Table 8: Pipeline, Global, First-in-Class Modulators of CD19, Scientific Assessment 62
Table 9: Pipeline, Global, First-in-Class Modulators of CD22, Scientific Assessment 65
Table 10: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Scientific Assessment 70
Table 11: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Pipeline Development 71
Table 12: Pipeline, Global, First-in-Class Modulators of Immunoglobulin-Like Transcript 7, Pipeline Development 71

List of Figures

Figure 1: SLE, Treatment Algorithm 14
Figure 2: Systemic Lupus Erythematosus, Global, Marketed Products 18
Figure 3: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Marketed Products 19
Figure 4: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 20
Figure 5: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 22
Figure 6: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 24
Figure 7: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety 26
Figure 8: Systemic Lupus Erythematosus, Global Pipeline Overview 28
Figure 9: Systemic Lupus Erythematosus, Global, Pipeline and Marketed Products 30
Figure 10: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Pipeline Programs Relative to Benlysta (belimumab) 32
Figure 11: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Products 34
Figure 12: Systemic Lupus Erythematosus, Global, Pipeline, Programs with Established Molecule Targets 36
Figure 13: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Programs 38
Figure 14: Pipeline, Global, First-in-Class IFN-? Inhibitors, Scientific assessment 41
Figure 15: Pipeline, Global, First-in-Class IFN-? Inhibitors, Pipeline Development 42
Figure 16: Pipeline, Global, First-in-Class CD74 Inhibitors, Pipeline Development 43
Figure 17: Pipeline, Global, First-in-Class Modulators of B7-Related Protein, Pipeline Development 45
Figure 18: Pipeline, Global, First-in-class modulators of IL-21, Scientific Assessment 47
Figure 19: Pipeline, Global, First-in-class Modulators of IL-21, Pipeline Development 48
Figure 20: Pipeline, Global, First-in-Class Modulators of IL-17 , Pipeline Development 50
Figure 21: Pipeline, Global, First-in-Class High Mobility Box Protein 1 Inhibitors, Pipeline Development 52

Figure 22: Pipeline, Global, First-in-class Modulators of APRIL, Pipeline Development 54
Figure 23: Pipeline, Global, First-in-class Modulators of CD4, Pipeline Development 56
Figure 24: Pipeline, Global, First-in-Class Modulators of CD40L, Scientific Assessment 58
Figure 25: Pipeline, Global, First-in-Class Modulators of CD40L, Pipeline Development 59
Figure 26: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Pipeline Development 61
Figure 27: Pipeline, Global, First-in-Class Modulators of CD19, Pipeline Development 63
Figure 28: Pipeline, Global, First-in-Class Modulators of CD22, Pipeline Development 66
Figure 29: Pipeline, Global, First-in-Class Modulators of Spleen Tyrosine Kinase, Scientific Assessment 68
Figure 30: Pipeline, Global, First-in-Class modulators of Spleen Tyrosine Kinase, Pipeline Development 69
Figure 31: Systemic Lupus Erythematosus, Global, Licensing Agreements, 2006–2013 (October) 75
Figure 32: Systemic Lupus Erythematosus, Global, Co-development deals, 2006–2013 (October) 77
Figure 33: Systemic Lupus Erythematosus, Global, First in-Class Programs Not Involved in Co-development or Licensing Deals 78

To order this report: Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
The Jevons Paradox suggests that when technological advances increase efficiency of a resource, it results in an overall increase in consumption. Writing on the increased use of coal as a result of technological improvements, 19th-century economist William Stanley Jevons found that these improvements led to the development of new ways to utilize coal. In his session at 19th Cloud Expo, Mark Thiele, Chief Strategy Officer for Apcera, will compare the Jevons Paradox to modern-day enterprise IT, e...
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, discussed how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved efficienc...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
SYS-CON Events announced today that CDS Global Cloud, an Infrastructure as a Service provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. CDS Global Cloud is an IaaS (Infrastructure as a Service) provider specializing in solutions for e-commerce, internet gaming, online education and other internet applications. With a growing number of data centers and network points around the world, ...
There are several IoTs: the Industrial Internet, Consumer Wearables, Wearables and Healthcare, Supply Chains, and the movement toward Smart Grids, Cities, Regions, and Nations. There are competing communications standards every step of the way, a bewildering array of sensors and devices, and an entire world of competing data analytics platforms. To some this appears to be chaos. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Bradley Holt, Developer Advocate a...